Corvus Pharmaceuticals (CRVS) Consolidated Net Income (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Consolidated Net Income of -$13.1 million in Q1 2026, down 12.73% quarter-over-quarter from -$11.6 million in Q4 2025, and down 183.23% on a YoY basis from $15.7 million in Q1 2025.
Corvus Pharmaceuticals (CRVS) Consolidated Net Income (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Consolidated Net Income history runs 12 years deep, the most recent figure standing at -$13.1 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 183.23% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$42.2 million (down 12.62% YoY), while the FY2025 annual figure was -$13.3 million, up 77.45% from the prior year.
- Consolidated Net Income was -$13.1 million for Q1 2026 at Corvus Pharmaceuticals, down from -$11.6 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $15.7 million in Q1 2025 to a low of -$39.5 million in Q3 2024.
- Historically, Consolidated Net Income has averaged -$8.2 million across 5 years, with a median of -$7.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Consolidated Net Income plunged 669.91% in 2024, then surged 364.98% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at -$5.7 million in 2022, then advanced by 7.36% to -$5.2 million in 2023, then sank by 89.35% to -$9.9 million in 2024, then retreated by 16.85% to -$11.6 million in 2025, then fell by 12.73% to -$13.1 million in 2026.
- The last three Consolidated Net Income figures came in at -$13.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Corvus Pharmaceuticals | 1.01 Bn | 771.25 Mn | - | -13.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.09 Mn |
| Dec 31, 2025 | -11.61 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Jun 30, 2025 | -7.61 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -39.54 Mn |
| Jun 30, 2024 | -3.69 Mn |
| Mar 31, 2024 | -5.94 Mn |
| Dec 31, 2023 | -5.25 Mn |
| Sep 30, 2023 | -5.14 Mn |
| Jun 30, 2023 | -5.22 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -5.67 Mn |
| Sep 30, 2022 | -12.47 Mn |
| Jun 30, 2022 | -7.01 Mn |
| Mar 31, 2022 | -7.41 Mn |
| Dec 31, 2021 | -6.81 Mn |
| Sep 30, 2021 | -9.05 Mn |
| Jun 30, 2021 | -11.29 Mn |